世界の黄斑変性症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Macular Degeneration Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3525 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、黄斑変性症治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ルセンティス、アイレア、アバスチン、スクアラミン、コンセプト、ランパリズマブ、その他）、用途別市場規模（50〜60歳、60〜70歳、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・黄斑変性症治療薬の市場動向 ・企業の競争状況、市場シェア ・黄斑変性症治療薬の種類別市場規模（ルセンティス、アイレア、アバスチン、スクアラミン、コンセプト、ランパリズマブ、その他） ・黄斑変性症治療薬の用途別市場規模（50〜60歳、60〜70歳、その他） ・黄斑変性症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・黄斑変性症治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・黄斑変性症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・黄斑変性症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・黄斑変性症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan） ・結論

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.

Market Analysis and Insights: Global Macular Degeneration Drugs Market
The global Macular Degeneration Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Macular Degeneration Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Macular Degeneration Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Macular Degeneration Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Macular Degeneration Drugs market.

Global Macular Degeneration Drugs Scope and Market Size
Macular Degeneration Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Macular Degeneration Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Lucentis
Eylea
Avastin
Squalamine
Conercept
Lampalizamab
Other

Segment by Application
50-60 Years Old
60-70 Years Old
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macular Degeneration Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lucentis
1.2.3 Eylea
1.2.4 Avastin
1.2.5 Squalamine
1.2.6 Conercept
1.2.7 Lampalizamab
1.2.8 Other
1.3 Market by Application
1.3.1 Global Macular Degeneration Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 50-60 Years Old
1.3.3 60-70 Years Old
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Macular Degeneration Drugs Market Perspective (2016-2027)
2.2 Macular Degeneration Drugs Growth Trends by Regions
2.2.1 Macular Degeneration Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Macular Degeneration Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Macular Degeneration Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Macular Degeneration Drugs Industry Dynamic
2.3.1 Macular Degeneration Drugs Market Trends
2.3.2 Macular Degeneration Drugs Market Drivers
2.3.3 Macular Degeneration Drugs Market Challenges
2.3.4 Macular Degeneration Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration Drugs Players by Revenue
3.1.1 Global Top Macular Degeneration Drugs Players by Revenue (2016-2021)
3.1.2 Global Macular Degeneration Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Macular Degeneration Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Macular Degeneration Drugs Revenue
3.4 Global Macular Degeneration Drugs Market Concentration Ratio
3.4.1 Global Macular Degeneration Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drugs Revenue in 2020
3.5 Macular Degeneration Drugs Key Players Head office and Area Served
3.6 Key Players Macular Degeneration Drugs Product Solution and Service
3.7 Date of Enter into Macular Degeneration Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Macular Degeneration Drugs Breakdown Data by Type
4.1 Global Macular Degeneration Drugs Historic Market Size by Type (2016-2021)
4.2 Global Macular Degeneration Drugs Forecasted Market Size by Type (2022-2027)

5 Macular Degeneration Drugs Breakdown Data by Application
5.1 Global Macular Degeneration Drugs Historic Market Size by Application (2016-2021)
5.2 Global Macular Degeneration Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Macular Degeneration Drugs Market Size (2016-2027)
6.2 North America Macular Degeneration Drugs Market Size by Type
6.2.1 North America Macular Degeneration Drugs Market Size by Type (2016-2021)
6.2.2 North America Macular Degeneration Drugs Market Size by Type (2022-2027)
6.2.3 North America Macular Degeneration Drugs Market Size by Type (2016-2027)
6.3 North America Macular Degeneration Drugs Market Size by Application
6.3.1 North America Macular Degeneration Drugs Market Size by Application (2016-2021)
6.3.2 North America Macular Degeneration Drugs Market Size by Application (2022-2027)
6.3.3 North America Macular Degeneration Drugs Market Size by Application (2016-2027)
6.4 North America Macular Degeneration Drugs Market Size by Country
6.4.1 North America Macular Degeneration Drugs Market Size by Country (2016-2021)
6.4.2 North America Macular Degeneration Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Macular Degeneration Drugs Market Size (2016-2027)
7.2 Europe Macular Degeneration Drugs Market Size by Type
7.2.1 Europe Macular Degeneration Drugs Market Size by Type (2016-2021)
7.2.2 Europe Macular Degeneration Drugs Market Size by Type (2022-2027)
7.2.3 Europe Macular Degeneration Drugs Market Size by Type (2016-2027)
7.3 Europe Macular Degeneration Drugs Market Size by Application
7.3.1 Europe Macular Degeneration Drugs Market Size by Application (2016-2021)
7.3.2 Europe Macular Degeneration Drugs Market Size by Application (2022-2027)
7.3.3 Europe Macular Degeneration Drugs Market Size by Application (2016-2027)
7.4 Europe Macular Degeneration Drugs Market Size by Country
7.4.1 Europe Macular Degeneration Drugs Market Size by Country (2016-2021)
7.4.2 Europe Macular Degeneration Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Macular Degeneration Drugs Market Size (2016-2027)
8.2 Asia-Pacific Macular Degeneration Drugs Market Size by Type
8.2.1 Asia-Pacific Macular Degeneration Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Macular Degeneration Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Macular Degeneration Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Macular Degeneration Drugs Market Size by Application
8.3.1 Asia-Pacific Macular Degeneration Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Macular Degeneration Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Macular Degeneration Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Macular Degeneration Drugs Market Size by Region
8.4.1 Asia-Pacific Macular Degeneration Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Macular Degeneration Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Macular Degeneration Drugs Market Size (2016-2027)
9.2 Latin America Macular Degeneration Drugs Market Size by Type
9.2.1 Latin America Macular Degeneration Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Macular Degeneration Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Macular Degeneration Drugs Market Size by Type (2016-2027)
9.3 Latin America Macular Degeneration Drugs Market Size by Application
9.3.1 Latin America Macular Degeneration Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Macular Degeneration Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Macular Degeneration Drugs Market Size by Application (2016-2027)
9.4 Latin America Macular Degeneration Drugs Market Size by Country
9.4.1 Latin America Macular Degeneration Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Macular Degeneration Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Macular Degeneration Drugs Market Size (2016-2027)
10.2 Middle East & Africa Macular Degeneration Drugs Market Size by Type
10.2.1 Middle East & Africa Macular Degeneration Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Macular Degeneration Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Macular Degeneration Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Macular Degeneration Drugs Market Size by Application
10.3.1 Middle East & Africa Macular Degeneration Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Macular Degeneration Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Macular Degeneration Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Macular Degeneration Drugs Market Size by Country
10.4.1 Middle East & Africa Macular Degeneration Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Macular Degeneration Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Macular Degeneration Drugs Introduction
11.1.4 Novartis Revenue in Macular Degeneration Drugs Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare Macular Degeneration Drugs Introduction
11.2.4 Bayer Healthcare Revenue in Macular Degeneration Drugs Business (2016-2021)
11.2.5 Bayer Healthcare Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Macular Degeneration Drugs Introduction
11.3.4 Roche Revenue in Macular Degeneration Drugs Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Neurotech Pharmaceuticals
11.4.1 Neurotech Pharmaceuticals Company Details
11.4.2 Neurotech Pharmaceuticals Business Overview
11.4.3 Neurotech Pharmaceuticals Macular Degeneration Drugs Introduction
11.4.4 Neurotech Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2016-2021)
11.4.5 Neurotech Pharmaceuticals Recent Development
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Details
11.5.2 Regeneron Pharmaceuticals Business Overview
11.5.3 Regeneron Pharmaceuticals Macular Degeneration Drugs Introduction
11.5.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2016-2021)
11.5.5 Regeneron Pharmaceuticals Recent Development
11.6 Allergan
11.6.1 Allergan Company Details
11.6.2 Allergan Business Overview
11.6.3 Allergan Macular Degeneration Drugs Introduction
11.6.4 Allergan Revenue in Macular Degeneration Drugs Business (2016-2021)
11.6.5 Allergan Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Macular Degeneration Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Lucentis
Table 3. Key Players of Eylea
Table 4. Key Players of Avastin
Table 5. Key Players of Squalamine
Table 6. Key Players of Conercept
Table 7. Key Players of Lampalizamab
Table 8. Key Players of Other
Table 9. Global Macular Degeneration Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Macular Degeneration Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Macular Degeneration Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Macular Degeneration Drugs Market Share by Regions (2016-2021)
Table 13. Global Macular Degeneration Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Macular Degeneration Drugs Market Share by Regions (2022-2027)
Table 15. Macular Degeneration Drugs Market Trends
Table 16. Macular Degeneration Drugs Market Drivers
Table 17. Macular Degeneration Drugs Market Challenges
Table 18. Macular Degeneration Drugs Market Restraints
Table 19. Global Macular Degeneration Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Macular Degeneration Drugs Market Share by Players (2016-2021)
Table 21. Global Top Macular Degeneration Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration Drugs as of 2020)
Table 22. Ranking of Global Top Macular Degeneration Drugs Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Macular Degeneration Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Macular Degeneration Drugs Product Solution and Service
Table 26. Date of Enter into Macular Degeneration Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Macular Degeneration Drugs Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Macular Degeneration Drugs Revenue Market Share by Type (2016-2021)
Table 30. Global Macular Degeneration Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Macular Degeneration Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Macular Degeneration Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Macular Degeneration Drugs Revenue Market Share by Application (2016-2021)
Table 34. Global Macular Degeneration Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Macular Degeneration Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Macular Degeneration Drugs Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Macular Degeneration Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Macular Degeneration Drugs Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Macular Degeneration Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Macular Degeneration Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Macular Degeneration Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Macular Degeneration Drugs Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Macular Degeneration Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Macular Degeneration Drugs Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Macular Degeneration Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Macular Degeneration Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Macular Degeneration Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Macular Degeneration Drugs Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Macular Degeneration Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Macular Degeneration Drugs Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Macular Degeneration Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Macular Degeneration Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Macular Degeneration Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Macular Degeneration Drugs Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Macular Degeneration Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Macular Degeneration Drugs Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Macular Degeneration Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Macular Degeneration Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Macular Degeneration Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Macular Degeneration Drugs Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Macular Degeneration Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Macular Degeneration Drugs Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Macular Degeneration Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Macular Degeneration Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Macular Degeneration Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Macular Degeneration Drugs Product
Table 69. Novartis Revenue in Macular Degeneration Drugs Business (2016-2021) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Bayer Healthcare Company Details
Table 72. Bayer Healthcare Business Overview
Table 73. Bayer Healthcare Macular Degeneration Drugs Product
Table 74. Bayer Healthcare Revenue in Macular Degeneration Drugs Business (2016-2021) & (US$ Million)
Table 75. Bayer Healthcare Recent Development
Table 76. Roche Company Details
Table 77. Roche Business Overview
Table 78. Roche Macular Degeneration Drugs Product
Table 79. Roche Revenue in Macular Degeneration Drugs Business (2016-2021) & (US$ Million)
Table 80. Roche Recent Development
Table 81. Neurotech Pharmaceuticals Company Details
Table 82. Neurotech Pharmaceuticals Business Overview
Table 83. Neurotech Pharmaceuticals Macular Degeneration Drugs Product
Table 84. Neurotech Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2016-2021) & (US$ Million)
Table 85. Neurotech Pharmaceuticals Recent Development
Table 86. Regeneron Pharmaceuticals Company Details
Table 87. Regeneron Pharmaceuticals Business Overview
Table 88. Regeneron Pharmaceuticals Macular Degeneration Drugs Product
Table 89. Regeneron Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2016-2021) & (US$ Million)
Table 90. Regeneron Pharmaceuticals Recent Development
Table 91. Allergan Company Details
Table 92. Allergan Business Overview
Table 93. Allergan Macular Degeneration Drugs Product
Table 94. Allergan Revenue in Macular Degeneration Drugs Business (2016-2021) & (US$ Million)
Table 95. Allergan Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Macular Degeneration Drugs Market Share by Type: 2020 VS 2027
Figure 2. Lucentis Features
Figure 3. Eylea Features
Figure 4. Avastin Features
Figure 5. Squalamine Features
Figure 6. Conercept Features
Figure 7. Lampalizamab Features
Figure 8. Other Features
Figure 9. Global Macular Degeneration Drugs Market Share by Application: 2020 VS 2027
Figure 10. 50-60 Years Old Case Studies
Figure 11. 60-70 Years Old Case Studies
Figure 12. Other Case Studies
Figure 13. Macular Degeneration Drugs Report Years Considered
Figure 14. Global Macular Degeneration Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Macular Degeneration Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Macular Degeneration Drugs Market Share by Regions: 2020 VS 2027
Figure 17. Global Macular Degeneration Drugs Market Share by Regions (2022-2027)
Figure 18. Global Macular Degeneration Drugs Market Share by Players in 2020
Figure 19. Global Top Macular Degeneration Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration Drugs as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Macular Degeneration Drugs Revenue in 2020
Figure 21. Global Macular Degeneration Drugs Revenue Market Share by Type (2016-2021)
Figure 22. Global Macular Degeneration Drugs Revenue Market Share by Type (2022-2027)
Figure 23. North America Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Macular Degeneration Drugs Market Share by Type (2016-2027)
Figure 25. North America Macular Degeneration Drugs Market Share by Application (2016-2027)
Figure 26. North America Macular Degeneration Drugs Market Share by Country (2016-2027)
Figure 27. United States Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Macular Degeneration Drugs Market Share by Type (2016-2027)
Figure 31. Europe Macular Degeneration Drugs Market Share by Application (2016-2027)
Figure 32. Europe Macular Degeneration Drugs Market Share by Country (2016-2027)
Figure 33. Germany Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Macular Degeneration Drugs Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Macular Degeneration Drugs Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Macular Degeneration Drugs Market Share by Region (2016-2027)
Figure 43. China Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Macular Degeneration Drugs Market Share by Type (2016-2027)
Figure 51. Latin America Macular Degeneration Drugs Market Share by Application (2016-2027)
Figure 52. Latin America Macular Degeneration Drugs Market Share by Country (2016-2027)
Figure 53. Mexico Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Macular Degeneration Drugs Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Macular Degeneration Drugs Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Macular Degeneration Drugs Market Share by Country (2016-2027)
Figure 59. Turkey Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Macular Degeneration Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Novartis Revenue Growth Rate in Macular Degeneration Drugs Business (2016-2021)
Figure 63. Bayer Healthcare Revenue Growth Rate in Macular Degeneration Drugs Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in Macular Degeneration Drugs Business (2016-2021)
Figure 65. Neurotech Pharmaceuticals Revenue Growth Rate in Macular Degeneration Drugs Business (2016-2021)
Figure 66. Regeneron Pharmaceuticals Revenue Growth Rate in Macular Degeneration Drugs Business (2016-2021)
Figure 67. Allergan Revenue Growth Rate in Macular Degeneration Drugs Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---